EUVIMEDEUVIMED entdecken
Open Access

Impact of PSMA PET Staging on Initial Treatment in Newly Diagnosed Prostate Cancer

Sean R Miller, Dana H Chung, Rachel T Gonzalez, William C Jackson, Megan E V Caram, Phoebe A Tsao, Kristian Stensland, Roman Gulati, Yashesh Shah, Daniel Wale, David Elliott, Tanner Caverly und 6 weitere

Journal of Nuclear Medicine · 2025

DOI: 10.2967/jnumed.125.270825 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Sean R Miller und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron Emission Tomography Computed Tomography, Glutamate Carboxypeptidase II, Antigens, Surface. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate-specific membrane antigen (PSMA) PET/CT has become a common staging modality for newly diagnosed high-risk and unfavorable intermediate-risk prostate cancer after showing improved sensitivity and specificity compared with conventional imaging in clinical trials. We aimed to assess the causal impact of PSMA PET staging on initial treatment selection in real-world practice.

Methods

We used observational data from the U.S. Veterans Health Administration to emulate a randomized controlled trial in which patients with newly diagnosed, unfavorable intermediate-, high-, and very-high-risk prostate cancer from January 2022 to December 2023 would have been randomized to undergo either upfront 18F- or 68Ga-PSMA PET staging or conventional imaging (99mTc bone scan and pelvic CT or MRI). Outcomes of interest included use of frontline androgen deprivation therapy (ADT), second-generation androgen receptor pathway inhibitors (ARPIs), radiotherapy, and radical prostatectomy. Weighted univariable Cox regression was performed to assess the effect of treatment group on each outcome, and 95% CIs were generated from 1,000 bootstrap replicates.

Results

In total, 9,049 patients met the criteria for inclusion. PSMA PET staging was associated with higher rates of any ADT use relative to conventional staging (adjusted hazard ratio [aHR], 1.26; 95% CI, 1.19-1.44), higher rates of ARPI use (aHR, 1.52; 95% CI, 1.33-1.78), lower rates of prostatectomy (aHR, 0.69; 95% CI, 0.56-0.83), and no significant effect on the use of radiotherapy (aHR, 1.10; 95% CI, 0.99-1.25). Compared with patients with PSMA stage N0M0, ARPI use was more common in patients with PSMA stage N1M0 (aHR, 6.87; 95% CI, 5.41-8.73) and PSMA stage M1 (aHR, 10.13; 95% CI, 8.16-1.2.58). Patients with PSMA N1M0 disease were much less likely to undergo prostatectomy compared with PSMA N0M0.

Conclusion

PSMA PET staging may be leading to fewer prostatectomies and higher use rates of ADT and ARPIs in the Veterans Health Administration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsPositron Emission Tomography Computed TomographyGlutamate Carboxypeptidase IIAntigens, SurfaceHumansMaleNeoplasm StagingAgedMiddle Aged

Stichwörter der Autor:innen

PET/CTPSMAemulated trialprostate cancerstaging

Substanzen

Glutamate Carboxypeptidase IIFOLH1 protein, humanAntigens, Surface

Autor:innen und Institutionen

  • Department of Radiation Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.
  • Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
  • University of Michigan School of Medicine, Ann Arbor, Michigan.
  • Department of Biostatistics, University of Michigan, Ann Arbor, Michigan.
  • Division of Medical Oncology, Department of Medicine, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.
  • Division of Hematology/Oncology, Department of Medicine, University of Michigan, Ann Arbor, Michigan.

Zitieren

APA

Miller, S. R., Chung, D. H., Gonzalez, R. T., Jackson, W. C., Caram, M. E. V., Tsao, P. A., Stensland, K., Gulati, R., Shah, Y., Wale, D., Elliott, D., Caverly, T., Hofer, T. P., Saini, S., Green, M. D., Schipper, M., Dess, R. T., & Bryant, A. K. (2025). Impact of PSMA PET Staging on Initial Treatment in Newly Diagnosed Prostate Cancer. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.270825

Vancouver

Miller SR, Chung DH, Gonzalez RT, Jackson WC, Caram MEV, Tsao PA, et al. Impact of PSMA PET Staging on Initial Treatment in Newly Diagnosed Prostate Cancer. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.125.270825

BibTeX
@article{Miller2025,
  author = {Miller, Sean R and Chung, Dana H and Gonzalez, Rachel T and Jackson, William C and Caram, Megan E V and Tsao, Phoebe A and Stensland, Kristian and Gulati, Roman and Shah, Yashesh and Wale, Daniel and Elliott, David and Caverly, Tanner and Hofer, Timothy P and Saini, Sameer and Green, Michael D and Schipper, Matthew and Dess, Robert T and Bryant, Alex K},
  title = {Impact of PSMA PET Staging on Initial Treatment in Newly Diagnosed Prostate Cancer},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  doi = {10.2967/jnumed.125.270825}
}
Kostenlos starten →